Operating Room Integration Market worth $3.3 billion by 2027 - Exclusive Report by MarketsandMarkets™

 "Operating Room Integration Market by Component (Hardware, Software, Service), Application (General, Orthopedic, & Cardiovascular Surgery), Device (Audio & Video Management, Display, Document Management), End User (Hospital, ASC) - Global Forecast to 2027", published by MarketsandMarkets™, the global Operating Room Integration Market is projected to reach USD USD 3.3 billion by 2027 from an estimated USD 1.9 billion in 2022, at a CAGR of 12.1% during the forecast period.

Browse in-depth TOC on "Operating Room Integration Market"
133 – Tables
33 – Figures
197 – Pages

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=160774667

Scope of the Report:

The study categorizes the operating room integration market based on product, type, technology, application, animal type, end user at regional and global level.

Global Operating room integration Market, by Component

•  Introduction
•  Software
• Services

Operating room integration Market, By Device Type

•  Introduction
• Display systems
• Document Management systems
• Audio & Video Management systems
• Other OR Integration devices

Operating room integration Market, By Application

•  Introduction
• General Surgery
• Orthopedic Surgery
• Cardiovascular Surgery
• Neurosurgery
• Thoracic Surgery
• Other Applications

Operating room integration Market, By End User

•  Introduction
• Hospitals
• Ambulatory Surgical Centers and Clinics

Global Operating room integration Market, by Region

• North America
• US
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Rest Of Europe
• Asia Pacific
• Japan
• China
• India
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Rest of LATAM
• Middle East & Africa

The Growth in this OR Integration Market is driven by the growing demand for technologically advanced solutions, the growing number of surgical procedures, rising funding initiatives for improving HCIT infrastructure, and increasing emphasis on cost control and efficiency improvement in hospitals. However, the high setup and operational costs, interoperability issues, and shortage of skilled surgeons in OR integration are expected to restrain market growth to a certain extent.

By component, the software segment accounted for the largest share of the operating room integration market in 2021.

The software segment is estimated to have the largest share by value of the operating room integration market. OR integration software helps streamline surgical workflows by enabling seamless communication between different systems and ensuring the effective and easier operation of these systems, preferably from a single source. Moreover, operating room integration software helps reduce surgical times, improves coordination between healthcare providers, and improves patient safety.

The orthopedic surgery segment is expected to witness the highest growth rate in the operating room integration market, by application.

Based on application, the orthopedic surgery segment is expected to register the highest CAGR during the forecast period. Factors responsible for the growth of this segment are recent technological advancements in robot-assisted orthopedic surgeries, rising preference for minimally invasive surgeries due to benefits in orthopedic applications (such as decreased procedural trauma, faster patient recovery, and decreased hospital stay).

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=160774667

North America dominated the operating room integration market in 2021.

North America accounted for the largest share of the OR Integration market in 2021, followed by Europe and Asia Pacific. The large share of North America in the global market can be attributed to the rising need to curtail healthcare costs, increasing patient preference for minimally invasive surgeries (owing to procedural benefits such as the lower risk of surgical-site infections, decreased patient injuries, and shorter hospitalization times), growing adoption rate of integrated operating rooms among healthcare providers, and the increasing number of ambulatory surgery centers.

Stryker Corporation (US), STERIS Plc (US), Karl Storz SE & Co. KG (Germany), Olympus Corporation (Japan), Getinge AB (Sweden) are the major players in this market. These companies are majorly focusing on the strategies such as agreements, collaborations, partnerships, and service launches in order to remain competitive and further increase their share in the Operating Room/OR Integration Market.

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/operating-room-integration-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/operating-room-integration.asp

 

In-Vitro Diagnostics Market worth $113.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

  “In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) – Global Forecast to 2026″, published by MarketsandMarkets™, the global IVD Market is projected to reach USD 113.1 billion by 2026 from USD 98.2 billion in 2021, at a CAGR of 2.9% during the forecast period.

 

Browse in-depth TOC on “In-Vitro Diagnostics Market”

347 – Tables
41 – Figures
426 – Pages

 

Download PDF Brochure:  -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703

 

The global IVD market is projected to reach USD 113.1 billion by 2026 from USD 98.2 billion in 2021, at a CAGR of 2.9% during the forecast period. The growth of the In-Vitro Diagnostics/IVD Market is mainly driven by the rising geriatric population and the subsequent growth in the prevalence of chronic and infectious diseases, increasing adoption of fully automated and POC instruments in developed regions, growing awareness regarding diseases diagnosis in developing regions, and growing R&D investments by industry players to launch new IVD products. Also, the development of disease-specific markers and tests is expected to offer potential growth opportunities to market players in the coming years. However, the unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.

 

In this report, the IVD market is segmented based on product & service, technology, application, end user, and region.

 

“Reagents & kits segment accounted for the largest share in the In-Vitro Diagnostics/IVD Market.”

Based on product and service, the In-Vitro Diagnostics Market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for the largest share of 68.1% of the market in 2020. Accessibility to a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders in the early stages are expected to drive the growth of this segment.

 

“Oncology segment is expected to witness the fastest growth in the forecast period.”

Based on application, the In-Vitro Diagnostics Market is segmented into infectious diseases, diabetes, Oncology, cardiology, drug testing/ pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and other applications. In 2020, infectious diseases accounted for 34.1% of the IVD market. The large share of this segment can be attributed to the rising prevalence of infectious diseases and multi-drug-resistant infectious diseases and the growing need for effective diagnostic tools for these diseases. However, the oncology segment is projected to grow at the highest CAGR of 6.6% during the forecast period. The increasing number of cancer cases across the globe, the growing demand for personalized medicine, and the availability of funding for cancer research are the major factors driving the market growth.

 

“Immunoassay/immunochemistry account for the largest share in the IVD market.”

Based on technology, the In-Vitro Diagnostics Market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation and hemostasis, urinalysis and other technologies. The immunoassay/immunochemistry segment accounted for 31% of the IVD technologies market in 2020. The growing preference for these technologies in clinical diagnostics over conventional methods and the ability of immunoassay/immunochemistry technologies to offer faster results with high sensitivity and accuracy are contributing to the growth of this market segment.

 

“Hospital laboratories accounted for the largest share of IVD market in 2020”

Based on the end user, the In-Vitro Diagnostics Market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. In 2020, hospital laboratories accounted for the largest share of 47% of the market, followed by clinical laboratories (23.8%) and POC testing centers (13%). Many diagnostic tests are carried out in hospitals. The acquisition of smaller physician practices and groups by hospitals is becoming a noticeable trend in the US healthcare industry; the continuation of this trend will support the market for hospital laboratories.

 

Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=703

“North America accounted for the largest share of the IVD market in 2020”

The In-Vitro Diagnostics Market is divided into five major regions— North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 39.8% of the market, followed by Europe (28%), Asia Pacific (22.9%), Latin America (6.5%), and the Middle East & Africa (2.9%). The In-Vitro Diagnostics/IVD Market in North America is well established, with the US being the major market in this region. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.

 

 

Scope of the Report:

By Product and Service

• Reagents & Kits
• Instruments
• Services
• Data Management Software

By Technology

• Immunoassay/ Immunochemistry
• Clinical chemistry
• Molecular diagnostics
• Hematology
• Microbiology
• Coagulation and Hemostasis
• Urinalysis
• Other Technologies

By Application

• Infectious diseases
• Diabetes
• Oncology
• Cardiology
• Drug Testing/ Pharmacogenomics
• Autoimmune diseases
• HIV/AIDS
• Nephrology
• Other applications

By End User

• Hospital laboratories
• Clinical laboratories
• Point-of-care testing centers
• Academic institutes
• Patients
• Other end users

By Country

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Australia
• Japan
• India
• Rest of APAC
• Latin America
• Brazil
• Rest of LATAM
• Middle East and Africa
• Turkey
• Rest of MEA

 

 

Key Market Players:

Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott (US), and Thermo Fisher Scientific (US) are the leading players in this market. Other players in this market are Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), DiaSorin (Italy), Ortho Clinical Diagnostics (US), and QIAGEN N.V. (Netherlands).

 

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441 Email: sales@marketsandmarkets.com

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/ivd-in-vitro-diagnostics-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/ivd-in-vitro-diagnostics.asp

 

 

Breast Biopsy Market worth $1,094 million by 2025 - Exclusive Report by MarketsandMarkets™

 "Breast Biopsy Market by Product (Needles, Tables, Assay Kit), by Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)) - Global Forecasts to 2025", published by MarketsandMarkets™, is projected to reach USD 1,094 million by 2025 from USD 725 million in 2020, at a CAGR of 8.6% during the forecast period.

Browse and in-depth TOC on "Breast Biopsy Market"             

129 - Tables
37 - Figures
187 - Pages

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189011805

The Technological advancements in the field of a breast biopsy and the rising incidence of breast cancer are the major factors driving the growth of this market. Additionally, the growing adoption of advanced techniques for breast cancer screening and rising government and private investments for improving breast cancer care are some of the other significant factors driving the growth of this market.

The biopsy needles segment accounted for the largest share of the market, by product, in 2019

Based on the product, the Breast Biopsy Market is segmented into biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other products. In 2019, the biopsy needles held significant share of the market. The major share of this segment is primarily attributed to the rising incidence of breast cancer and the growing breast cancer diagnosis rate in developing countries. Moreover, rising preference to the minimally invasive procedures and favorable reimbursement scenario in both developed as well as developing countries will further drive the market growth.

Technological advancements to drive the growth of NGS-based biopsy segment during the forecast period

Based on guidance, the Breast Biopsy Market is segmented into image-guided biopsy and liquid biopsy. The liquid biopsy segment is further divided into NGS-based, PCR-based, and Microarray-based biopsy. Among these, the NGS-based biopsy segment is expected to register significant growth over the forecast period. Technological advancements and new product launches are other factors leading to segment growth. Companies operating in the segment, such as Illumina, Inc. (US), Thermo Fisher Scientific (US), and Fluxion Biosciences Inc. (US), are focusing on high R&D investment to deliver novel and advanced platforms for tumor diagnosis.

Needle biopsy segment is anticipated to hold major share of the global Breast Biopsy Market in terms of type

Based on type, the market is segmented into needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. In 2019, the needle breast biopsy held a major share of the market. Needle biopsy has replaced conventional excisional biopsy as the standard diagnostic procedure for breast cancer. Rising adoption of core needle biopsy by healthcare professionals due to advantages such as high sensitivity and specificity and technological advancements are driving the growth of the segment.

Get 10% Customization Research Report: - https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=189011805  

North America to hold a significant share of the Breast Biopsy Market during the forecast period

The market is segmented into five regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American region accounted for the largest share of the market in 2019. The rising incidence of breast cancer, easy accessibility and high adoption of advanced diagnostic technologies (owing to the significant per capita annual healthcare expenditure in the US and Canada), presence of a favorable reimbursement scenario, and the rapidly increasing geriatric population in the region are some of the major factors driving the growth of the market in North America.

The major players operating in the Breast Biopsy Market are Hologic, Inc. (US), Becton, Dickinson and Company (US), Danaher Corporation (US), Merit Medical Systems (US), QIAGEN (Netherlands), Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation (US), Illumina, Inc. (US), and Fluxion Biosciences Inc (US), among others.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biopsy-devices-breast-biopsy-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/biopsy-devices-breast-biopsy.asp 

 

Wearable Injectors Market worth $11.5 billion by 2026 - Exclusive Report by MarketsandMarkets™

 " Wearable Injectors Market by Product Type(On-Body and Off-Body), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases), Technology(Spring-based, Motor Driven, Rotary Pump, Expanding Battery), Care Setting (Hospitals) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 11.5 billion by 2026 from USD 7.2 billion in 2021, at a CAGR of 9.9% during the forecast period.

Browse in-depth TOC on "Wearable Injectors Market"
114 – Tables
51 – Figures
196 – Pages

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004

The Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenario in major markets, and technological advancements in injector devices. However, the preference for alternative drug delivery modes, high costs, and a poor reimbursement structure in developing countries are expected to limit the adoption of wearable injectors to a certain extent.

By Type, the on-body injectors segment is expected to account for the largest share of the wearable injectors market

By type, the global market is segmented into on-body injectors and off-body injectors. The on-body injectors segment accounted for the largest share in the forecast year. The large share of this segment can be attributed to the patients ease to deliver a precise amount of drug to the body over a controlled period of time.

On the basis of technology, spring based segment is expected to account for the largest share of the market

Based on technology, the wearable injectors market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and other technologies. The spring-based technology segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to the rising demand for adhesive patches, as these devices are user-friendly and enable patients to accurately deliver the required drug subcutaneously.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=100771004

On the basis of therapy, diabetes segment is expected to account for the largest share of the market

Based on therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (such as Parkinson's disease, thalassemia, and primary immunodeficiency disorders). The diabetes segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to The high burden of diabetes across the globe, coupled with the growing availability of wearable injectors for the treatment of these diseases, is driving the growth of this market segment.

On the basis of end user, hospitals and clinics segment holds the highest market share in the wearable injectors market

Based on end user, the market is segmented into hospitals and clinics and home healthcare settings. The hospitals and clinics segment accounted for a larger market share during the forecast period. The large share of this segment can primarily be attributed to the rising preference for the self-administration of medication and the increasing need to curb healthcare costs. In addition, the growing demand for technologically developed drug delivery approaches, which lower the hospitalization rate and require minimal expertise, is expected to boost the growth of the home healthcare settings segment.

Speak to Analyst: -https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=100771004

North America to dominate the wearable injectors market during the forecast period

The wearable injector market in North America accounted for the largest market during the forecast period. The large share of North America in this market is to the rising prevalence of chronic and lifestyle-related diseases and the presence of advanced healthcare infrastructure in the region. However, the Europe market is estimated to grow at the highest CAGR during the forecast period owing to factors such as the Increasing prevalence of chronic diseases, Government support for drug development in Germany, Rising focus on biosimilar innovation in the UK, Favorable reimbursement scenario for various treatment options in France.

Prominent players in the wearable injectors market include Becton, Dickinson and Company(US), Ypsomed(Switzerland), Amgen(US), Subcuject(Denmark), Enable Injections, Inc(US), Medtronic Plc(Ireland), Insulet Corporation(US), United Therapeutics Corp (Us), CeQur SA(Switzerland), Sensile Medical(Switzerland).

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/wearable-injector-market.asp
Content Source:  https://www.marketsandmarkets.com/PressReleases/wearable-injector.asp